GILEAD

CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)

	2022				2023				2024
(in millions)	**Mar 31**	**Jun 30**	**Sep 30**	**Dec 31**	**Mar 31**	**Jun 30**	**Sep 30**	**Dec 31**	**Mar 31**
Assets									
Cash, cash equivalents and marketable debt securities	$ 6,752	$ 7,000	$ 6,942	$ 7,630	$ 7,200	$ 8,001	$ 8,021	$ 8,428	$ 4,718
Accounts receivable, net	3,787	4,118	4,354	4,777	4,162	4,229	4,790	4,660	4,669
Inventories	2,675	2,587	2,602	2,820	3,010	3,181	3,202	3,366	3,363
Property, plant and equipment, net	5,253	5,299	5,349	5,475	5,479	5,540	5,572	5,317	5,321
Intangible assets, net	30,331	29,885	29,440	28,894	28,348	27,750	27,152	26,454	23,428
Goodwill	8,314	8,314	8,314	8,314	8,314	8,314	8,314	8,314	8,314
Other assets	5,968	5,667	5,556	5,261	5,364	5,322	5,323	5,586	6,479
Total assets	$ 63,080	$ 62,870	$ 62,557	$ 63,171	$ 61,876	$ 62,337	$ 62,373	$ 62,125	$ 56,292
Liabilities and Stockholders' Equity									
Current liabilities	$ 8,558	$ 9,220	$ 10,423	$ 11,237	$ 10,528	$ 13,964	$ 11,945	$ 11,280	$ 13,015
Long-term liabilities	34,607	33,435	31,077	30,725	30,409	27,279	28,186	28,096	25,822
Stockholders' equity	19,915	20,215	21,057	21,209	20,939	21,094	22,242	22,749	17,455
Total liabilities and stockholders' equity	$ 63,080	$ 62,870	$ 62,557	$ 63,171	$ 61,876	$ 62,337	$ 62,373	$ 62,125	$ 56,292

Certain amounts and percentages may not sum or recalculate due to rounding.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - GAAP
(unaudited)

(in millions, except percentages and per share amounts)	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2022 FY22	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2023 FY23	2024 Q1
Revenues:											
Product sales	$ 6,534	$ 6,138	$ 6,978	$ 7,333	$ 26,982	$ 6,306	$ 6,564	$ 6,994	$ 7,070	$ 26,934	$ 6,647
Royalty, contract and other revenues	56	122	64	56	299	46	35	56	45	182	39
Total revenues	6,590	6,260	7,042	7,389	27,281	6,352	6,599	7,051	7,115	27,116	6,686
Costs and expenses:											
Cost of goods sold	1,424	1,442	1,395	1,396	5,657	1,401	1,442	1,565	2,090	6,498	1,552
Research and development expenses	1,178	1,102	1,149	1,548	4,977	1,447	1,407	1,457	1,408	5,718	1,520
Acquired in-process research and development expenses	8	330	448	158	944	481	236	91	347	1,155	4,131
In-process research and development impairment	2,700	—	—	—	2,700	—	—	—	50	50	2,430
Selling, general and administrative expenses	1,083	1,357	1,213	2,020	5,673	1,319	1,849	1,315	1,608	6,090	1,375
Total costs and expenses	6,393	4,231	4,205	5,122	19,951	4,647	4,934	4,428	5,503	19,511	11,008
Operating income (loss)	197	2,029	2,837	2,267	7,330	1,705	1,665	2,623	1,612	7,605	(4,322)
Interest expense	238	242	229	227	935	230	230	232	252	944	254
Other (income) expense, net	111	284	176	9	581	174	(152)	72	(293)	(198)	(91)
(Loss) income before income taxes	(152)	1,503	2,432	2,031	5,814	1,300	1,588	2,318	1,653	6,859	(4,486)
Income tax (benefit) expense	(164)	368	646	398	1,248	316	549	146	236	1,247	(315)
Net income (loss)	12	1,135	1,786	1,633	4,566	985	1,039	2,172	1,417	5,613	(4,170)
Net loss attributable to noncontrolling interest	(7)	(9)	(3)	(7)	(26)	(26)	(6)	(8)	(12)	(52)	—
Net income (loss) attributable to Gilead	$ 19	$ 1,144	$ 1,789	$ 1,640	$ 4,592	$ 1,010	$ 1,045	$ 2,180	$ 1,429	$ 5,665	$ (4,170)
Basic earnings (loss) per share attributable to Gilead	$ 0.02	$ 0.91	$ 1.43	$ 1.31	$ 3.66	$ 0.81	$ 0.84	$ 1.75	$ 1.15	$ 4.54	$ (3.34)
Shares used in basic earnings (loss) per share attributable to Gilead calculation	1,255	1,256	1,255	1,252	1,255	1,248	1,249	1,248	1,248	1,248	1,247
Diluted earnings (loss) per share attributable to Gilead	$ 0.02	$ 0.91	$ 1.42	$ 1.30	$ 3.64	$ 0.80	$ 0.83	$ 1.73	$ 1.14	$ 4.50	$ (3.34)
Shares used in diluted earnings (loss) per share attributable to Gilead calculation	1,262	1,260	1,261	1,264	1,262	1,261	1,258	1,257	1,256	1,258	1,247
Cash dividends declared per share	$ 0.73	$ 0.73	$ 0.73	$ 0.73	$ 2.92	$ 0.75	$ 0.75	$ 0.75	$ 0.75	$ 3.00	$ 0.77
Product gross margin	78.2 %	76.5 %	80.0 %	81.0 %	79.0 %	77.8 %	78.0 %	77.6 %	70.4 %	75.9 %	76.6 %
Research and development expenses as a % of revenues	17.9 %	17.6 %	16.3 %	20.9 %	18.2 %	22.8 %	21.3 %	20.7 %	19.8 %	21.1 %	22.7 %
Selling, general and administrative expenses as a % of revenues	16.4 %	21.7 %	17.2 %	27.3 %	20.8 %	20.8 %	28.0 %	18.6 %	22.6 %	22.5 %	20.6 %
Operating margin	3.0 %	32.4 %	40.3 %	30.7 %	26.9 %	26.8 %	25.2 %	37.2 %	22.7 %	28.0 %	(64.6)%
Effective tax rate	107.9 %	24.5 %	26.6 %	19.6 %	21.5 %	24.3 %	34.6 %	6.3 %	14.3 %	18.2 %	7.0 %

Certain amounts and percentages may not sum or recalculate due to rounding.

SELECTED CASH FLOW INFORMATION
(unaudited)

(in millions)	2022 Q1	2022 Q2	2022 Q3	2022 Q4	FY22	2023 Q1	2023 Q2	2023 Q3	2023 Q4	FY23	2024 Q1
Net cash provided by operating activities	$ 1,840	$ 1,802	$ 2,863	$ 2,566	$ 9,072	$ 1,744	$ 2,337	$ 1,756	$ 2,168	$ 8,006	$ 2,219
Net cash used in investing activities	(1,070)	(308)	(713)	(374)	(2,466)	(826)	(483)	(229)	(726)	(2,265)	(2,207)
Net cash used in financing activities	(1,794)	(1,003)	(2,118)	(1,554)	(6,469)	(1,406)	(1,101)	(1,518)	(1,100)	(5,125)	(1,361)
Effect of exchange rate changes on cash and cash equivalents	(18)	(48)	(72)	75	(63)	13	14	(7)	37	57	(18)
Net change in cash and cash equivalents	(1,042)	443	(40)	713	74	(476)	768	1	380	673	(1,367)
Cash and cash equivalents, beginning of period	5,338	4,296	4,739	4,699	5,338	5,412	4,936	5,704	5,705	5,412	6,085
Cash and cash equivalents, end of period	$ 4,296	$ 4,739	$ 4,699	$ 5,412	$ 5,412	$ 4,936	$ 5,704	$ 5,705	$ 6,085	$ 6,085	$ 4,718

(in millions)	2022 Q1	2022 Q2	2022 Q3	2022 Q4	FY22	2023 Q1	2023 Q2	2023 Q3	2023 Q4	FY23	2024 Q1
Net cash provided by operating activities	$ 1,840	$ 1,802	$ 2,863	$ 2,566	$ 9,072	$ 1,744	$ 2,337	$ 1,756	$ 2,168	$ 8,006	$ 2,219
Capital expenditures	(247)	(143)	(157)	(181)	(728)	(109)	(139)	(122)	(214)	(585)	(105)
Free cash flow(1)	$ 1,593	$ 1,659	$ 2,706	$ 2,386	$ 8,344	$ 1,635	$ 2,199	$ 1,633	$ 1,954	$ 7,421	$ 2,114

Certain amounts and percentages may not sum or recalculate due to rounding.

(1) Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section of our Press Release, issued by Gilead Sciences, Inc. on April 25, 2024 on Form 8-K, which is available on http://investors.gilead.com.

GILEAD

NON-GAAP FINANCIAL INFORMATION[1]
(unaudited)

(in millions, except percentages and per share amounts)	2022 Q1	2022 Q2	2022 Q3	2022 Q4	FY22	2023 Q1	2023 Q2	2023 Q3	2023 Q4	FY23	2024 Q1
Non-GAAP:											
Cost of goods sold	$ 825	$ 886	$ 923	$ 968	$ 3,602	$ 871	$ 861	$ 985	$ 980	$ 3,697	$ 974
Research and development expenses	$ 1,150	$ 1,102	$ 1,173	$ 1,544	$ 4,968	$ 1,439	$ 1,377	$ 1,453	$ 1,452	$ 5,720	$ 1,403
Acquired in-process research and development expenses[2]	$ 8	$ 330	$ 448	$ 158	$ 944	$ 481	$ 236	$ 91	$ 347	$ 1,155	$ 4,131
Selling, general and administrative expenses	$ 1,083	$ 1,272	$ 1,212	$ 2,020	$ 5,587	$ 1,318	$ 1,848	$ 1,298	$ 1,597	$ 6,060	$ 1,295
Other expense (income), net	$ 15	$ (20)	$ (20)	$ (52)	$ (77)	$ (82)	$ (83)	$ (96)	$ (104)	$ (365)	$ (104)
Diluted earnings (loss) per share	$ 2.12	$ 1.58	$ 1.90	$ 1.67	$ 7.26	$ 1.37	$ 1.34	$ 2.29	$ 1.72	$ 6.72	$ (1.32)
Product gross margin	87.4 %	85.6 %	86.8 %	86.8 %	86.6 %	86.2 %	86.9 %	85.9 %	86.1 %	86.3 %	85.4 %
Research and development expenses as a % of revenues	17.5 %	17.6 %	16.7 %	20.9 %	18.2 %	22.6 %	20.9 %	20.6 %	20.4 %	21.1 %	21.0 %
Selling, general and administrative expenses as a % of revenues	16.4 %	20.3 %	17.2 %	27.3 %	20.5 %	20.7 %	28.0 %	18.4 %	22.4 %	22.3 %	19.4 %
Operating margin	53.5 %	42.7 %	46.7 %	36.5 %	44.6 %	35.3 %	34.5 %	45.7 %	38.5 %	38.7 %	(16.7)%
Effective tax rate	18.4 %	19.3 %	22.4 %	16.8 %	19.3 %	18.9 %	21.0 %	7.0 %	17.1 %	15.2 %	(29.8)%

Certain amounts and percentages may not sum or recalculate due to rounding.

[1] Please refer to our disclosures in the Non-GAAP Financial Information section of our Press Release, issued by Gilead Sciences, Inc. on April 25, 2024 on Form 8-K, which is available on http://investors.gilead.com. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 5 - 6.

[2] Equal to GAAP financial information.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(unaudited)

(in millions, except percentages and per share amounts)	2022 Q1	2022 Q2	2022 Q3	2022 Q4	FY22	2023 Q1	2023 Q2	2023 Q3	2023 Q4	FY23	2024 Q1
Cost of goods sold reconciliation:											
GAAP cost of goods sold	$ 1,424	$ 1,442	$ 1,395	$ 1,396	$ 5,657	$ 1,401	$ 1,442	$ 1,565	$ 2,090	$ 6,498	$ 1,552
Acquisition-related – amortization[1]	(557)	(556)	(472)	(428)	(2,013)	(530)	(581)	(581)	(580)	(2,271)	(579)
Restructuring	(42)	—	—	—	(42)	—	—	—	(479)	(479)	—
Other[2]	—	—	—	—	—	—	—	—	(51)	(51)	—
Non-GAAP cost of goods sold	$ 825	$ 886	$ 923	$ 968	$ 3,602	$ 871	$ 861	$ 985	$ 980	$ 3,697	$ 974
Product gross margin reconciliation:											
GAAP product gross margin	78.2 %	76.5 %	80.0 %	81.0 %	79.0 %	77.8 %	78.0 %	77.6 %	70.4 %	75.9 %	76.6 %
Acquisition-related – amortization[1]	8.5 %	9.1 %	6.8 %	5.8 %	7.5 %	8.4 %	8.8 %	8.3 %	8.2 %	8.4 %	8.7 %
Restructuring	0.6 %	— %	— %	— %	0.2 %	— %	— %	— %	6.8 %	1.8 %	— %
Other[2]	— %	— %	— %	— %	— %	— %	— %	— %	0.7 %	0.2 %	— %
Non-GAAP product gross margin	87.4 %	85.6 %	86.8 %	86.8 %	86.6 %	86.2 %	86.9 %	85.9 %	86.1 %	86.3 %	85.4 %
Research and development expenses reconciliation:											
GAAP research and development expenses	$ 1,178	$ 1,102	$ 1,149	$ 1,548	$ 4,977	$ 1,447	$ 1,407	$ 1,457	$ 1,408	$ 5,718	$ 1,520
Acquisition-related – other costs[3]	(10)	—	24	(1)	13	(8)	(30)	1	59	22	(66)
Restructuring	(18)	—	—	(4)	(22)	—	—	(5)	(15)	(20)	(50)
Non-GAAP research and development expenses	$ 1,150	$ 1,102	$ 1,173	$ 1,544	$ 4,968	$ 1,439	$ 1,377	$ 1,453	$ 1,452	$ 5,720	$ 1,403
IPR&D impairment reconciliation:											
GAAP IPR&D impairment	$ 2,700	$ —	$ —	$ —	$ 2,700	$ —	$ —	$ —	$ 50	$ 50	$ 2,430
IPR&D impairment	(2,700)	—	—	—	(2,700)	—	—	—	(50)	(50)	(2,430)
Non-GAAP IPR&D impairment	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —
Selling, general and administrative expenses reconciliation:											
GAAP selling, general and administrative expenses	$ 1,083	$ 1,357	$ 1,213	$ 2,020	$ 5,673	$ 1,319	$ 1,849	$ 1,315	$ 1,608	$ 6,090	$ 1,375
Acquisition-related – other costs[3]	—	—	(2)	(1)	(3)	(1)	(1)	—	—	(2)	(67)
Restructuring	—	—	1	1	2	—	—	(17)	(11)	(28)	(13)
Other[2]	—	(85)	—	—	(85)	—	—	—	—	—	—
Non-GAAP selling, general and administrative expenses	$ 1,083	$ 1,272	$ 1,212	$ 2,020	$ 5,587	$ 1,318	$ 1,848	$ 1,298	$ 1,597	$ 6,060	$ 1,295
Operating income (loss) reconciliation:											
GAAP operating income (loss)	$ 197	$ 2,029	$ 2,837	$ 2,267	$ 7,330	$ 1,705	$ 1,665	$ 2,623	$ 1,612	$ 7,605	$ (4,322)
Acquisition-related – amortization[1]	557	556	472	428	2,013	530	581	581	580	2,271	579
Acquisition-related – other costs[3]	10	—	(22)	2	(10)	9	31	(1)	(59)	(20)	133
Restructuring	60	—	(1)	2	62	—	—	22	505	527	63
IPR&D impairment	2,700	—	—	—	2,700	—	—	—	50	50	2,430
Other[2]	—	85	—	—	85	—	—	—	51	51	—
Non-GAAP operating income (loss)	$ 3,524	$ 2,670	$ 3,286	$ 2,699	$ 12,180	$ 2,243	$ 2,277	$ 3,224	$ 2,739	$ 10,484	$ (1,117)
Operating margin reconciliation:											
GAAP operating margin	3.0 %	32.4 %	40.3 %	30.7 %	26.9 %	26.8 %	25.2 %	37.2 %	22.7 %	28.0 %	(64.6)%
Acquisition-related – amortization[1]	8.5 %	8.9 %	6.7 %	5.8 %	7.4 %	8.3 %	8.8 %	8.2 %	8.1 %	8.4 %	8.7 %
Acquisition-related – other costs[3]	0.2 %	— %	(0.3)%	— %	— %	0.1 %	0.5 %	— %	(0.8)%	(0.1)%	2.0 %
Restructuring	0.9 %	— %	— %	— %	0.2 %	— %	— %	0.3 %	7.1 %	1.9 %	0.9 %
IPR&D impairment	41.0 %	— %	— %	— %	9.9 %	— %	— %	— %	0.7 %	0.2 %	36.3 %
Other[2]	— %	1.4 %	— %	— %	0.3 %	— %	— %	— %	0.7 %	0.2 %	— %
Non-GAAP operating margin	53.5 %	42.7 %	46.7 %	36.5 %	44.6 %	35.3 %	34.5 %	45.7 %	38.5 %	38.7 %	(16.7) %

GILEAD

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)
(unaudited)

(in millions, except per share amounts)	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2022 FY22	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2023 FY23	2024 Q1
Other (income) expense, net reconciliation:											
GAAP other (income) expense, net	$ 111	$ 284	$ 176	$ 9	$ 581	$ 174	$ (152)	$ 72	$ (293)	$ (198)	$ (91)
(Loss) gain from equity securities, net	(96)	(303)	(197)	(61)	(657)	(256)	69	(168)	189	(167)	(14)
Non-GAAP other (income) expense, net	$ 15	$ (20)	$ (20)	$ (52)	$ (77)	$ (82)	$ (83)	$ (96)	$ (104)	$ (365)	$ (104)
Effective tax rate reconciliation:											
GAAP effective tax rate	107.9 %	24.5 %	26.6 %	19.6 %	21.5 %	24.3 %	34.6 %	6.3 %	14.3 %	18.2 %	7.0 %
Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments[4]	(89.5)%	(5.2)%	(4.1)%	(2.8)%	(2.1)%	(5.4)%	(13.5)%	0.7 %	2.8 %	(3.0)%	(36.8)%
Non-GAAP effective tax rate	18.4 %	19.3 %	22.4 %	16.8 %	19.3 %	18.9 %	21.0 %	7.0 %	17.1 %	15.2 %	(29.8)%
Net income (loss) attributable to Gilead reconciliation:											
GAAP net income (loss) attributable to Gilead	$ 19	$ 1,144	$ 1,789	$ 1,640	$ 4,592	$ 1,010	$ 1,045	$ 2,180	$ 1,429	$ 5,665	$ (4,170)
Acquisition-related – amortization[1]	443	442	379	346	1,610	422	461	461	460	1,805	458
Acquisition-related – other costs[3]	10	—	(23)	1	(12)	6	26	(1)	(59)	(29)	103
Restructuring	45	—	—	2	47	—	—	17	414	431	54
IPR&D impairment	2,057	—	—	—	2,057	—	—	—	35	35	1,819
Loss (gain) from equity securities, net	64	308	198	60	630	257	(70)	164	(171)	180	53
Discrete and related tax charges[4]	38	31	49	57	175	29	227	58	12	326	39
Other[2]	—	59	—	—	59	—	—	—	40	40	—
Non-GAAP net income (loss) attributable to Gilead	$ 2,676	$ 1,985	$ 2,391	$ 2,106	$ 9,158	$ 1,725	$ 1,688	$ 2,879	$ 2,161	$ 8,454	$ (1,644)
Diluted earnings (loss) per share reconciliation:											
GAAP diluted earnings (loss) per share	$ 0.02	$ 0.91	$ 1.42	$ 1.30	$ 3.64	$ 0.80	$ 0.83	$ 1.73	$ 1.14	$ 4.50	$ (3.34)
Acquisition-related – amortization[1]	0.35	0.35	0.30	0.27	1.28	0.33	0.37	0.37	0.37	1.43	0.37
Acquisition-related – other costs[3]	0.01	—	(0.02)	—	(0.01)	0.01	0.02	—	(0.05)	(0.02)	0.08
Restructuring	0.04	—	—	—	0.04	—	—	0.01	0.33	0.34	0.04
IPR&D impairment	1.63	—	—	—	1.63	—	—	—	0.03	0.03	1.46
Loss (gain) from equity securities, net	0.05	0.24	0.16	0.05	0.50	0.20	(0.06)	0.13	(0.14)	0.14	0.04
Discrete and related tax charges[4]	0.03	0.02	0.04	0.05	0.14	0.02	0.18	0.05	0.01	0.26	0.03
Other[2]	—	0.05	—	—	0.05	—	—	—	0.03	0.03	—
Non-GAAP diluted earnings (loss) per share	$ 2.12	$ 1.58	$ 1.90	$ 1.67	$ 7.26	$ 1.37	$ 1.34	$ 2.29	$ 1.72	$ 6.72	$ (1.32)
Non-GAAP adjustment summary:											
Cost of goods sold adjustments	$ 599	$ 556	$ 472	$ 428	$ 2,055	$ 530	$ 581	$ 581	$ 1,110	$ 2,801	$ 579
Research and development expenses adjustments	28	—	(24)	4	9	8	30	4	(44)	(2)	117
IPR&D impairment adjustments	2,700	—	—	—	2,700	—	—	—	50	50	2,430
Selling, general and administrative expenses adjustments	—	85	1	—	86	1	1	17	11	30	80
Total non-GAAP adjustments to costs and expenses	3,327	641	450	432	4,850	539	612	602	1,127	2,879	3,205
Other (income) expense, net, adjustments	96	303	197	61	657	256	(69)	168	(189)	167	14
Total non-GAAP adjustments before income taxes	3,423	945	646	493	5,507	795	543	770	938	3,046	3,219
Income tax effect of non-GAAP adjustments above	(803)	(135)	(93)	(84)	(1,116)	(109)	(126)	(129)	(218)	(583)	(732)
Discrete and related tax charges[4]	38	31	49	57	175	29	227	58	12	326	39
Total non-GAAP adjustments after tax	$ 2,657	$ 841	$ 602	$ 466	$ 4,566	$ 715	$ 644	$ 699	$ 732	$ 2,789	$ 2,526

Certain amounts and percentages may not sum or recalculate due to rounding.

(1) Relates to amortization of acquired intangibles and inventory step-up charges.

(2) The adjustment in Cost of goods sold relates to a write-off of an intangible asset related to the restructuring of our collaboration with Galapagos NV during the fourth quarter of 2023. The adjustment in Selling, general and administrative expense relates to donations of equity securities to the Gilead Foundation, a California nonprofit organization.

(3) Relates primarily to integration expenses, contingent consideration fair value adjustments and other expenses associated with Gilead's acquisitions of MYR GmbH, MiroBio, Ltd., Tmunity Therapeutics, Inc., XinThera, Inc. and CymaBay Therapeutics, Inc.

(4) Represents discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and transfers of intangible assets from a foreign subsidiary to Ireland and the United States.

GILEAD

TOTAL REVENUE SUMMARY
(unaudited)

(in millions)	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2022 FY22	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2023 FY23	2024 Q1
Product sales[1]:											
HIV	$ 3,707	$ 4,228	$ 4,487	$ 4,772	$ 17,194	$ 4,190	$ 4,626	$ 4,667	$ 4,693	$ 18,175	$ 4,342
Liver Disease	635	682	788	694	2,798	675	711	706	691	2,784	737
Oncology	420	527	578	614	2,139	670	728	769	765	2,932	789
Other	236	256	200	252	946	199	243	216	201	859	224
Total product sales excluding Veklury	4,998	5,693	6,053	6,333	23,077	5,733	6,308	6,358	6,350	24,750	6,092
Veklury	1,535	445	925	1,000	3,905	573	256	636	720	2,184	555
Total product sales	6,534	6,138	6,978	7,333	26,982	6,306	6,564	6,994	7,070	26,934	6,647
Royalty, contract and other revenues	56	122	64	56	299	46	35	56	45	182	39
Total revenues	$ 6,590	$ 6,260	$ 7,042	$ 7,389	$ 27,281	$ 6,352	$ 6,599	$ 7,051	$ 7,115	$ 27,116	$ 6,686

Certain amounts and percentages may not sum or recalculate due to rounding.

[1] See Product Sales Summary on pages 8-10 for more details.

PRODUCT SALES SUMMARY
(unaudited)

(in millions)	2022 Q1	2022 Q2	2022 Q3	2022 Q4	FY22	2023 Q1	2023 Q2	2023 Q3	2023 Q4	FY23	2024 Q1
HIV											
Biktarvy – U.S.	$ 1,706	$ 2,095	$ 2,286	$ 2,423	$ 8,510	$ 2,161	$ 2,439	2,504	$ 2,588	$ 9,692	$ 2,315
Biktarvy – Europe	261	268	278	295	1,103	304	302	313	333	1,253	365
Biktarvy – Rest of World	184	193	201	200	777	212	237	268	188	905	265
	2,151	2,556	2,766	2,918	10,390	2,677	2,979	3,085	3,109	11,850	2,946
Descovy – U.S.	311	397	444	479	1,631	395	460	460	457	1,771	371
Descovy – Europe	32	32	28	26	118	25	25	25	25	100	26
Descovy – Rest of World	31	32	28	31	123	29	31	26	28	114	29
	374	460	500	537	1,872	449	516	511	509	1,985	426
Genvoya – U.S.	457	482	502	543	1,983	417	455	433	447	1,752	332
Genvoya – Europe	77	72	71	64	284	55	56	47	48	205	49
Genvoya – Rest of World	48	29	27	33	136	29	29	23	22	103	21
	582	582	600	640	2,404	501	540	503	517	2,060	403
Odefsey – U.S.	232	255	276	295	1,058	230	267	257	258	1,012	223
Odefsey – Europe	96	97	86	85	364	76	74	74	71	294	76
Odefsey – Rest of World	11	12	12	11	47	11	11	11	11	44	11
	339	364	374	392	1,469	317	351	343	340	1,350	310
Symtuza - Revenue share[(1)] – U.S.	86	80	85	97	348	98	84	96	104	382	104
Symtuza - Revenue share[(1)] – Europe	44	42	40	42	168	36	33	32	32	133	33
Symtuza - Revenue share[(1)] – Rest of World	3	4	4	3	14	4	3	3	3	13	3
	132	126	130	142	530	138	120	131	139	529	141
Other HIV[(2)] – U.S.	71	73	67	78	290	62	74	56	46	238	60
Other HIV[(2)] – Europe	40	53	37	52	182	32	31	28	25	116	45
Other HIV[(2)] – Rest of World	18	14	13	14	59	13	15	9	9	47	12
	129	140	117	143	530	108	120	94	79	401	117
Total HIV – U.S.	2,862	3,383	3,661	3,914	13,820	3,364	3,778	3,807	3,899	14,848	3,405
Total HIV – Europe	550	562	541	566	2,219	528	521	519	533	2,102	596
Total HIV – Rest of World	295	282	285	293	1,155	298	326	341	261	1,226	342
	3,707	4,228	4,487	4,772	17,194	4,190	4,626	4,667	4,693	18,175	4,342
Liver Disease											
Sofosbuvir/Velpatasvir[(3)] – U.S.	162	227	241	214	844	204	223	215	216	859	248
Sofosbuvir/Velpatasvir[(3)] – Europe	83	75	131	67	355	90	84	76	74	323	79
Sofosbuvir/Velpatasvir[(3)] – Rest of World	85	74	84	87	331	90	90	85	89	355	78
	330	376	455	369	1,530	385	397	377	378	1,537	405
Vemlidy – U.S.	80	97	129	123	429	87	96	112	115	410	95
Vemlidy – Europe	9	9	9	8	35	9	10	9	10	38	11
Vemlidy – Rest of World	111	89	90	89	379	103	113	106	92	414	119
	200	195	228	220	842	199	219	228	217	862	225
Other Liver Disease[(4)] – U.S.	37	39	44	47	167	27	37	49	39	152	42
Other Liver Disease[(4)] – Europe	31	41	31	33	135	41	37	33	38	150	47
Other Liver Disease[(4)] – Rest of World	37	32	30	25	124	23	21	20	19	83	19
	105	112	104	105	426	91	95	102	96	385	107
Total Liver Disease – U.S.	279	363	413	384	1,440	318	356	376	370	1,421	385
Total Liver Disease – Europe	123	124	170	108	525	140	131	119	121	511	137
Total Liver Disease – Rest of World	233	195	204	202	833	217	225	211	200	852	215
	$ 635	$ 682	$ 788	$ 694	$ 2,798	$ 675	$ 711	$ 706	$ 691	$ 2,784	$ 737

Certain amounts and percentages may not sum or recalculate due to rounding.

(1) Represents Gilead's revenue from cobicistat ("C"), emtricitabine ("FTC") and tenofovir alafenamide ("TAF") in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

(2) Includes Atripla, Complera/Eviplera, Emtriva, Sunlenca, Stribild, Truvada and Tybost.

(3) Includes Epclusa and the authorized generic version of Epclusa sold by Gilead's separate subsidiary, Asegua Therapeutics LLC ("Asegua").

(4) Includes Ledipasvir/Sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Sovaldi, Viread and Vosevi.

PRODUCT SALES SUMMARY (continued)
(unaudited)

(in millions)	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2022 FY22	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2023 FY23	2024 Q1
Veklury											
Veklury – U.S.	$ 801	$ 41	$ 336	$ 395	$ 1,575	$ 252	$ 97	$ 258	$ 364	$ 972	$ 315
Veklury – Europe	304	126	130	142	702	111	52	65	181	408	70
Veklury – Rest of World	430	278	458	462	1,628	209	107	313	175	805	169
	1,535	445	925	1,000	3,905	573	256	636	720	2,184	555
Oncology											
Cell Therapy											
Tecartus – U.S.	47	53	60	61	221	59	56	64	66	245	55
Tecartus – Europe	15	20	20	19	75	27	29	27	27	110	36
Tecartus – Rest of World	1	—	1	1	3	3	4	4	5	15	8
	63	73	81	82	299	89	88	96	98	370	100
Yescarta – U.S.	125	193	210	219	747	210	217	197	187	811	170
Yescarta – Europe	77	85	91	103	355	121	133	154	140	547	158
Yescarta – Rest of World	9	17	16	15	57	28	30	40	42	140	52
	211	295	317	337	1,160	359	380	391	368	1,498	380
Total Cell Therapy – U.S.	172	246	270	281	968	269	272	261	253	1,055	225
Total Cell Therapy – Europe	92	105	111	122	430	148	162	181	167	658	195
Total Cell Therapy – Rest of World	10	17	17	17	60	31	34	45	46	156	60
	274	368	398	419	1,459	448	469	486	466	1,869	480
Trodelvy											
Trodelvy – US	119	120	139	146	525	162	189	201	226	777	206
Trodelvy – Europe	25	35	38	44	143	54	53	62	48	217	68
Trodelvy – Rest of World	2	3	3	4	12	6	17	21	24	68	36
	146	159	180	195	680	222	260	283	299	1,063	309
Total Oncology – U.S.	292	366	409	427	1,494	431	462	462	479	1,833	431
Total Oncology – Europe	117	140	149	166	573	202	215	243	216	875	262
Total Oncology – Rest of World	11	21	20	21	73	37	51	65	70	224	96
	420	527	578	614	2,139	670	728	769	765	2,932	789
Other											
AmBisome – U.S.	25	15	9	9	57	6	20	12	4	43	14
AmBisome – Europe	66	63	63	66	258	60	69	63	68	260	70
AmBisome – Rest of World	53	54	33	42	182	49	61	39	39	189	60
	144	132	105	117	497	116	151	115	111	492	144
Other[(5)] – U.S.	69	86	72	104	331	62	64	69	64	261	59
Other[(5)] – Europe	15	26	11	13	65	12	10	9	9	40	9
Other[(5)] – Rest of World	9	13	13	18	53	9	17	23	17	66	12
	93	125	96	135	449	83	92	101	90	367	80
Total Other – Rest of World	94	101	80	113	388	69	85	82	68	304	73
Total Other – U.S.	81	88	75	79	323	72	80	72	77	301	79
Total Other – Europe	62	67	46	61	235	58	78	62	56	255	71
	236	256	200	252	946	199	243	216	201	859	224
Total product sales – U.S.	4,329	4,254	4,900	5,234	18,716	4,434	4,777	4,985	5,180	19,377	4,609
Total product sales – Europe	1,174	1,042	1,064	1,061	4,342	1,053	999	1,017	1,128	4,197	1,144
Total product sales – Rest of World	1,031	842	1,013	1,037	3,924	819	788	992	762	3,361	894
	$ 6,534	$ 6,138	$ 6,978	$ 7,333	$ 26,982	$ 6,306	$ 6,564	$ 6,994	$ 7,070	$ 26,934	$ 6,647

Certain amounts and percentages may not sum or recalculate due to rounding.

(5) Includes Cayston, Jyseleca, Letairis, Ranexa and Zydelig.